The measurement of the unbound or free phenytoin concentration is indicated
in several situations, including uremia. In patients with uremia, metaboli
tes of phenytoin and other substances accumulate and can displace phenytoin
from its protein binding sites, with a consequent increase in the free fra
ction of drug. Some of the phenytoin metabolites that accumulate in uremia
can cross-react with phenytoin immunoassays. In this study the authors eval
uated four free phenytoin immunoassays compared with a high-performance liq
uid chromatography (HPLC) method: the Roche COBAS Integra, the Syva EMIT 20
00, the Opus INNOFLUOR, and the Abbott TDx. All four methods demonstrated g
ood precision, with interday coefficients of variation of less than or equa
l to 5% and comparable recoveries using quality control material. Two of th
e methods, the EMIT 2000 and COBAS Integra, showed excellent agreement with
the HPLC method using samples from patients both with normal renal functio
n and with renal insufficiency. The other two methods, the INNOFLUOR and TD
x, showed average positive biases for the therapeutic range of 3-7% and 21-
22%, respectively, compared with the HPLC method for samples from patients
with normal renal function, and average positive biases of 24-32% and 75-81
%, respectively, with samples from patients with uremia.